investment.com

Enliven Therapeutics, Inc. — insider transactions

5 transactions on record · CIK 1672619

Aggregates

computed from the filings below
Purchases, 12m
0
count of open-market buys
Sales, 12m
5
count of open-market sales
Buy / sell ratio, 12m
0.00
purchases per sale
Distinct insiders, 12m
1
Bought, 3m
$0
Sold, 3m
$264.2K
Median disclosure lag
4.0 d
trade date to filing date
Largest single trade, 24m
$145.9K
2026-09-17
Director share, 12m
0.0%
of transactions where role is stated
Current run
5 sells
consecutive same-direction transactions
Net 3m flow
-$264.2K
purchases minus sales
Total on record
5

Transactions

5 most recent shown
DisclosedTradedLag, dInsiderRoleTransactionSharesPriceValueSource
2026-09-212026-09-174Collins Helen LouiseCHIEF MEDICAL OFFICEROpen market sale1,844$50.71$93.5Kfiling
2026-09-212026-09-174Collins Helen LouiseCHIEF MEDICAL OFFICEROpen market sale2,916$50.03$145.9Kfiling
2026-09-212026-09-174Collins Helen LouiseCHIEF MEDICAL OFFICERExercise of derivative5,000$0.00—filing
2026-09-212026-09-174Collins Helen LouiseCHIEF MEDICAL OFFICERExercise of derivative5,000$2.48$12.4Kfiling
2026-09-212026-09-174Collins Helen LouiseCHIEF MEDICAL OFFICEROpen market sale240$51.48$12.4Kfiling

Source: U.S. Securities and Exchange Commission, EDGAR

Enliven Therapeutics, Inc. insider transactions — 5 filings on record — investment.com